Silodosin
| File:Silodosin.png | |
| Systematic (IUPAC) name | |
|---|---|
|
1-(3-hydroxypropyl)-5-[(2R)-({2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]indoline-7-carboxamide | |
| Clinical data | |
| Pregnancy category |
|
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 32% |
| Protein binding | 97% |
| Metabolism | Hepatic glucuronidation (UGT2B7-mediated); also minor CYP3A4 involvement |
| Biological half-life | 13±8 hours |
| Excretion | Renal and fecal |
| Identifiers | |
| CAS Number | 160970-54-7 |
| ATC code | G04CA04 (WHO) |
| PubChem | CID 5312125 |
| IUPHAR/BPS | 493 |
| Chemical data | |
| Formula | C25H32F3N3O4 |
| Molar mass | 495.534 g/mol[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
Silodosin also known as KMD-3213 is an α1-adrenoceptor antagonist with high uroselectivity. [1]
History
Silodosin received its first marketing approval in Japan in May 2006 under the tradename Urief, which is jointly marketed by Kissei Pharmaceutical Co., Ltd. and Daiichi Sankyo Pharmaceutical Co., Ltd.
Kissei licensed the US, Canadian, and Mexican rights for silodosin to Watson Pharmaceuticals, Inc. in 2004.
On February 12, 2008, Watson announced that the New Drug Application submitted to the United States Food and Drug Administration for silodosin has been accepted for filing. FDA approved this drug on October 9th, 2008.[2] Silodosin is marketed under the tradename Rapaflo.
Pharmacology
Since Silodosin is a highly selective inhibitor of the α1A adrenergic receptor, it causes practically no orthostatic hypotension (in contrast to other α1 blockers). On the other side, the high selectivity seems to cause more problems with ejaculation.[3]
As alpha 1A-adrenoceptor antagonists are being investigated as a means to male birth control due to their ability to inhibit ejaculation but not orgasm, a trial with 15 male volunteers was conducted. While silodosin was completely efficacious in preventing the release of semen in all subjects, 12 out of the 15 patients reported mild discomfort upon orgasm. The men also reported the psychosexual side effect of being strongly dissatisfied by their lack of ejaculation.[4] Despite the incidence of side effects, the drug still appears to be a promising candidate for a male oral contraceptive drug.
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />External links
| 40px | This antihypertensive-related article is a stub. You can help ssf by expanding it. |
| 40px | This drug article relating to the genito-urinary system is a stub. You can help ssf by expanding it. |
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- ↑ "Drugs.com, Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia". Retrieved 2008-02-13.
- ↑ Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel 2008/2009
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- Pages with script errors
- Pages with broken file links
- Drugs with non-standard legal status
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- 2Fix
- Alpha blockers
- Phenethylamines
- Phenol ethers
- Indolines
- Organofluorides
- Amides
- Alcohols
- Antihypertensive agent stubs
- Genito-urinary system drug stubs
